SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a significant rebound following a period of intense short selling and recent earnings. Community members are actively discussing the potential for a short squeeze, citing high short interest and positive analyst ratings, and celebrating the stock's resilience amid market volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending as investors react to the company's announcement regarding the completion of its BlueBird 6 satellite and the planned launch schedule, generating excitement about upcoming milestones. The community is buzzing with bullish sentiment, anticipating new all-time highs and significant long-term growth potential. Some traders are closely monitoring short positions and expecting a potential squeeze.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to a broader crypto market rally and recent strategic restructuring, including the sale of its loyalty business and appointment of a fintech veteran to its board. The community is actively discussing the potential for a short squeeze and the company's transformation into a pure-play digital asset platform. Bullish sentiment is growing, with some eyeing prior highs and speculating about future partnerships and expansion.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending due to a mix of positive price action and news of increased competition in the stablecoin space. Community members are debating whether the stock will continue its upward momentum or face a pullback due to potential rate cuts impacting revenue. Traders are actively discussing technical levels and potential short squeezes, with some highlighting the impact of insider selling and upcoming share unlock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss potential catalysts, including upcoming data presentations at the World Muscle Society (WMS) Congress and the anticipation of positive news regarding SRP-9003. Community members are weighing the potential for a short squeeze given the stock's high short interest, with some expressing optimism for a significant price increase and buyout speculation, while remaining cautiously optimistic.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase ($COIN) is trending due to significant call buying activity and a recent price surge, sparking bullish sentiment. The community is actively discussing potential price targets and the correlation with Bitcoin's movements, while also debating its valuation relative to peers like Robinhood. Some are drawing comparisons to past financial crises, adding a layer of caution to the enthusiasm.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is experiencing increased attention, with community members citing a potential breakout and government investment possibilities as catalysts. Discussions revolve around recent news, high call option activity, and the significance of rare earth elements for national security. The stock's breakout is leading to speculation about future price targets and institutional interest.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending as investors react to Berkshire Hathaway's acquisition of OXY's OxyChem unit, leading to discussions around debt reduction and potential share buybacks. Community perspectives are mixed, with some questioning the strategic rationale behind selling a profitable business unit while others see it as a necessary step to strengthen the balance sheet. The news has sparked debate about the company's future direction and exposure to oil price fluctuations.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community anticipates potential ETF approvals and discusses the implications of David Schwartz stepping down as CTO.  Bullish sentiment is fueled by discussions around institutional adoption, tokenization, and cross-border payment utility, with some speculating on significant price movement.  Despite positive news, XRP struggles to break the $3 mark, leading to frustration and debate about market manipulation and future potential.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors discuss the potential for significant revenue growth through acquisitions and AI-driven operational improvements within the fragmented building products industry. Community members are debating the company's current valuation and future prospects, with some expressing frustration over recent stock performance while others remain confident in the management's long-term strategy. Discussions also include potential acquisition targets and the impact of macroeconomic factors like interest rate cuts on the housing market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

Outlook Therapeutics, Inc. (OTLK) announced on Thursday that the U.S. Food and Drug Administration (FDA) has declined to approve its investigational drug Lytenava for the treatment of wet age-related macular degeneration. Shares of the company nosedived by over 66% in Thursday’s pre-market session following the announcement.The agency cited a lack of substantial evidence of effectiveness as the basis for its decision. Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older. Wet age-related macular degeneration (wet AMD) is an advanced form of AMD where abnormal, leaky blood vessels grow under the retina, leading to rapid vision loss.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> trended within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.The agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/28/3140631/0/en/Outlook-Therapeutics-Provides-Regulatory-Update-on-U-S-Food-and-Drug-Administration-Review-of-ONS-5010-LYTENAVA-bevacizumab-vikg-for-the-Treatment-of-Wet-AMD.html">noted</a> in its letter to the company that the drug did not meet the primary efficacy endpoint in a study and recommended that confirmatory evidence of efficacy be submitted to support the application.CEO Bob Jahr said that the company is very disappointed with this outcome and intends to meet with the agency to receive additional clarity on requirements for approval.“It is important to also note that the CRL (letter) identified no other outstanding deficiencies in our BLA (application),” Jahr added.The company also said that it intends to continue its efforts to expand Lytenava into additional markets in Europe. It has already been granted Marketing Authorization by the European Commission in the European Union and Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.OTLK is up by 26% this year but down by 68% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lisa-cook-to-sue-trump-administration-firing-her-federal-reserve-board/chsH6GARdjs">Lisa Cook To Sue Trump Administration For Firing Her From Federal Reserve Board: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why

The US FDA declined to approve the firm’s investigational drug Lytenava for the treatment of wet age-related macular degeneration, citing a lack of substantial evidence of effectiveness.

Equity

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -4.76% and -40.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for July 30th

BYD, ROKU, OTLK, E and PII have been added to the Zacks Rank #1 (Strong Buy) List on July 30, 2025.

Outlook Therapeutics Poised for Growth: Strong Buy Recommendation Amidst Positive Clinical and Financial Developments

Analyst Tim Chiang from Capital One Financial assigned a Buy rating on Outlook Therapeutics (OTLK Research Report) and keeping the price target a...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Acquires 1,882 Shares

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin purchased 1,882 shares of the firm's stock in a transaction dated Thursday, March 28th. The shares were...

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Purchases 1,882 Shares of Stock

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin bought 1,882 shares of Outlook Therapeutics stock in a transaction dated Thursday, March 28th. The stock was...

Outlook Therapeutics files for $300M mixed securities shelf

Outlook Therapeutics files for $300M mixed securities shelf...

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Outlook Therapeutics Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$1.07
Prev Close	$1.04
Open	$1.04
Dividend Yield	0.00%
50-Day Moving Average	$1.62
Beta	0.75
Avg. Volume	3.27M
PE Ratio	-0.95

52-Week High	$6.98
52-Week Low	$0.79
Market Capitalization	$46.2M
EPS (Annual)	-$4.06
Price to Book	-1.22
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OTLK News

OTLK Outlook Therapeutics Inc